Skip to Main Content
Services Talent Knowledge
Site Search
Menu

PressRelease

December 1, 2025

Matthew Gino Joins Barclay Damon

Barclay Damon announces Matthew Gino, associate, has joined Barclay Damon’s Environmental, Regulatory, and Energy Practice Areas. His primary office is New York City.

Gino supports clients across the firm’s platform on matters involving federal permitting, environmental review, and the development of energy and other infrastructure projects. Prior to joining Barclay Damon, Gino was an attorney adviser in the Office of General Counsel with the Federal Energy Regulatory Commission. His background deepens Barclay Damon’s bench in guiding clients through federal environmental and energy regulatory frameworks, including NEPA review, project permitting, and agency engagement.

Barclay Damon attorneys team across offices and practices to provide customized, targeted solutions grounded in industry knowledge and a deep understanding of our clients' businesses. With approximately 300 attorneys, Barclay Damon is a leading regional law firm that operates from a strategic platform of offices in Albany, Boston, Buffalo, New Haven, New York City, Rochester, Syracuse, Washington DC, and Toronto. Our firm serves clients across the country and, for some practices, provides US legal services around the globe. For more information, visit our award-winning website at barclaydamon.com.

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks